Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 10,453 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Kind Clear all
Terminated Phase 1Phase 2 Interventional Results available

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

NCT05756166
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy, Biospecimen Collection, Celecoxib, Computed Tomography, Interferon Alpha-2, Magnetic Resonance Imaging, Pembrolizumab, Rintatolimod
Procedure · Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Results available

Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure

NCT02917031
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Heart Failure
Interventions
Saxagliptin, Sitagliptin, Placebo to match saxagliptin, Placebo to match sitagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Torrance, California • Upland, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 28, 2026, 10:22 AM EDT
Active, not recruiting No phase listed Observational

Heart Attack Research Program- Imaging Study

NCT02905357
View directory record Official record
Conditions
Myocardial Infarction
Interventions
OCT, CMR
Device · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 99 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 28, 2026, 10:22 AM EDT
Withdrawn Phase 2 Interventional

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

NCT00387530
View directory record Official record
Conditions
Gastric Cancer, Head and Neck Cancer, Lymphoma, Lymphoproliferative Disorder
Interventions
oral sodium phenylbutyrate, valganciclovir, polymerase chain reaction, protein expression analysis, biopsy
Drug · Genetic · Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacogenomics of Thiazolidinediones

NCT01135394
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Pioglitazone
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
35 Years to 64 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome

NCT02251431
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease, Left Ventricular Diastolic Dysfunction
Interventions
BYDUREON, Placebo
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 28, 2026, 10:22 AM EDT
Completed No phase listed Observational

Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass.

NCT02781272
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Pelvic imaging, Blood draw, Imaging guided biopsy, surgical biopsy or surgical excision
Procedure
Lead sponsor
Angle plc
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Results available

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis

NCT01216072
View directory record Official record
Conditions
Relapsing Forms of Multiple Sclerosis
Interventions
Fingolimod, Standard MS DMTs
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
142
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 125 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 28, 2026, 10:22 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

NCT03914612
View directory record Official record
Conditions
Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Dedifferentiated Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Mixed Cell Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
Carboplatin, Computed Tomography, Paclitaxel, Pembrolizumab, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Procedure · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
370
States / cities
Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 272 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Case Selection and Treatment Protocol for Immediate Dental Implants in the Esthetic Zone

NCT02154581
View directory record Official record
Conditions
Jaw, Edentulous, Partially, Acquired Absence of Single Tooth
Interventions
SLActive implant
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Not applicable Interventional Results available

Evaluation of an Karajishi TS Investigational Blood Glucose Monitoring System

NCT02041377
View directory record Official record
Conditions
Diabetes
Interventions
Karajishi TS Investigational Blood Glucose Monitoring System
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Escondido, California • Renton, Washington
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 28, 2026, 10:22 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Unobtrusive Monitoring of Affective Symptoms and Cognition Using Keyboard Dynamics (UnMASCK)

NCT04358900
View directory record Official record
Conditions
Mood Disorders, Major Depressive Disorder, Bipolar Disorder I, Bipolar Disorder II, Persistent Depressive Disorder (Dysthymia), Cyclothymia
Interventions
Not listed
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
25 Years to 50 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 28, 2026, 10:22 AM EDT
Not yet recruiting Phase 2 Interventional

Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer

NCT07634601
View directory record Official record
Conditions
Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage III Endometrial Cancer, Stage IV Endometrial Cancer
Interventions
Biospecimen Collection, Computed Tomography, Elacestrant, Everolimus, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Results available

Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2

NCT01346475
View directory record Official record
Conditions
Genital Herpes
Interventions
Valacyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Oct 28, 2026, 10:22 AM EDT
Terminated Phase 3 Interventional

To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy

NCT00120328
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
SPP301
Drug
Lead sponsor
Speedel Pharma Ltd.
Industry
Eligibility
21 Years to 80 Years
Enrollment
2,364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2007 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Not applicable Interventional Results available

Home-Based Intervention for Chronic Pain in Adults With Sickle Cell Disease

NCT04906707
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
EaseVRx, Audio-only version of EaseVRx
Device · Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 28, 2026, 10:22 AM EDT
Completed No phase listed Observational Results available

An Observational Study to Understand Challenges Associated With Progression of Insulin Therapy in Type 2 Diabetes

NCT01400971
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
4,299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
22
States / cities
Little Rock, Arkansas • Orlando, Florida • Wellington, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 28, 2026, 10:22 AM EDT
Not listed Not applicable Interventional

Evaluation of Intra-Abdominal Fat Extraction Using HydraSolve T2D™ in Obese Subjects With Type 2 Diabetes

NCT03953963
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Resistance
Interventions
HydraSolve T2D™
Device
Lead sponsor
Medality Medical
Industry
Eligibility
22 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

NCT02284893
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Dapagliflozin, Sitagliptin, Placebo matching with Saxagliptin, Placebo matching with Dapagliflozin, Placebo matching with Sitagliptin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
40
States / cities
Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Not applicable Interventional

Comparing Different Types of Physical Therapy for Treating People With a Meniscal Tear and Osteoarthritis

NCT03059004
View directory record Official record
Conditions
Meniscal Degeneration, Osteoarthritis, Knee
Interventions
TeMPO Home Exercise Program, Motivational SMS Messages, In-Clinic Topical Therapy, In-Clinic Exercise Therapy
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years to 85 Years
Enrollment
879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
4
States / cities
Boston, Massachusetts • Buffalo, New York • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Phase 4 Interventional Results available

Intravesicular Onabotulinumtoxin A in Interstitial Cystitis

NCT02297100
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
Onabotulinumtoxin A, injections upper aspect of trigone of urinary bladder, injections on posterior bladder wall excluding the trigone
Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 28, 2026, 10:22 AM EDT
Active, not recruiting Phase 3 Interventional

VK2735 for Weight Management Phase 3

NCT07104500
View directory record Official record
Conditions
Weight Loss
Interventions
VK2735
Drug
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
135
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 119 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 28, 2026, 10:22 AM EDT
Not yet recruiting Not applicable Interventional

Virtual Lifestyle Medicine Group Visits for High Blood Pressure

NCT07698509
View directory record Official record
Conditions
Hypertension
Interventions
Lifestyle Medicine Virtual group, Usual Care Group
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 28, 2026, 10:22 AM EDT
Completed Not applicable Interventional

A Study of the Elopement Prevention and Safety Training Program

NCT02383732
View directory record Official record
Conditions
Elopement, Autism Spectrum Disorder
Interventions
Universal Safety Measures Module (All participants), Proximity Training Module (Bolting Prevention Participants), Check-In Training Module (Wandering Prevention Participants)
Behavioral
Lead sponsor
Emory University
Other
Eligibility
4 Years to 12 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 28, 2026, 10:22 AM EDT